Sarepta Therapeutics | SRPT

Stock Price
18.71
Daily Change
0.25 1.35%
Monthly
15.07%
Yearly
-85.49%
Q3 Forecast
18.55

Peers Price Chg Day Year Date
Daiichi Sankyo 3,621.00 5.00 0.14% -35.87% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Sarepta Therapeutics traded at $18.71 this Friday September 5th, increasing $0.25 or 1.35 percent since the previous trading session. Looking back, over the last four weeks, Sarepta Therapeutics gained 15.07 percent. Over the last 12 months, its price fell by 85.49 percent. Looking ahead, we forecast Sarepta Therapeutics to be priced at 18.55 by the end of this quarter and at 18.10 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.